BridgeBio to Present Follow-up Data of Phase 1 NSCLC Drug at International Conference Next Month

Announcement of Additional Data from Phase 1 Clinical Trial of 'BBT-176'

Bridge Biotherapeutics announced on the 30th that the presentation of follow-up data from the Phase 1 clinical trial of the 4th generation non-small cell lung cancer treatment candidate 'BBT-176' has been confirmed at the '2023 World Conference on Lung Cancer (IASLC 2023 WCLC)' opening in Singapore on the 9th of next month.

Bridge Biotherapeutics logo. [Image provided by Bridge Biotherapeutics]

According to the released abstract, the follow-up data from the Phase 1 clinical trial of BBT-176, developed as a 4th generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), will newly present ▲ improved tolerability and medication adherence of BBT-176 with twice-daily dosing ▲ patient cases showing partial response (PR) with tumor size reduction of over 30% in the modified twice-daily dosing group.

This follow-up data from the Phase 1 clinical trial will be disclosed through a presentation by Professor Sunmin Lim of Yonsei Cancer Center at the EGFR and human epidermal growth factor receptor 2 (HER2) targeted therapy session held locally in Singapore around 3 p.m. on the 11th of next month during the World Conference on Lung Cancer.

Jungkyu Lee, CEO of Bridge Biotherapeutics, stated, "We will promptly complete the expansion cohort of the ongoing Phase 1 clinical trial of BBT-176 and increase the possibility of accelerated approval through the Phase 1 end-of-study meeting with the U.S. Food and Drug Administration (FDA). As a leading developer in the global competition for 4th generation EGFR inhibitors, we also plan to soon showcase achievements in global technology licensing and partnerships."

Meanwhile, Bridge Biotherapeutics continues to develop treatments in the non-small cell lung cancer field by developing 4th generation targeted lung cancer therapies BBT-176 and BBT-207, while also conducting companion diagnostic research related to gene mutations. BBT-176 was selected as a supported project in the 'New Drug Clinical Development' category of the 2021 National New Drug Development Project and is receiving support from the Korea Drug Development Fund (KDDF).

This content was produced with the assistance of AI translation services.